The following study looked at how the translocation associated oncogene SYT-SSX2 reprograms stem cells to become malignant in synovial sarcoma:
http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE26565
They suggest FGFR2 is a promising target for future synovial sarcoma therapy...